PCE, PREVENT, SCORE2-Diabetes: Understanding the CVD Risk Prediction Tools in People with Diabetes

by Prateek Chopra | June 11, 2026 | Diabetes Conferences | ADA 2026 | 0 comments

Need for Improved Risk Assessment:

  • Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality among people with diabetes, highlighting the need for accurate risk prediction tools to guide preventive strategies.
  • Traditional risk assessment has relied on the 2013 Pooled Cohort Equations (PCE), which estimate 10-year risk of a first atherosclerotic cardiovascular disease (ASCVD) event but do not adequately account for heart failure (HF), chronic kidney disease (CKD), or diabetes-specific cardiovascular risk.

PREVENT Risk Equations:

  • PREVENT was developed using contemporary cohorts and incorporates a broader range of cardiometabolic risk factors.
  • The model predicts both ASCVD and HF outcomes.
  • External validation demonstrated strong predictive performance, with C-statistics ranging from 0.736 to 0.830 and calibration slopes close to 1.0 across sexes.

Diabetes and CKD-Specific Risk Stratification:

  • Estimated 10-year CVD risk was:
    • 2.7% in individuals without diabetes or CKD.
    • 6.2% in individuals with diabetes alone.
    • 5.3% in individuals with CKD alone.
    • 11.8% in individuals with both diabetes and CKD.
  • PREVENT also provides 30-year risk estimates and risk percentiles to support earlier preventive interventions.

SCORE2-Diabetes Model:

  • SCORE2 and SCORE2-Diabetes were developed and validated using large European populations.
  • SCORE2-Diabetes incorporates diabetes-specific variables, including:
    • Age at diabetes diagnosis.
    • HbA1c levels.
    • Estimated glomerular filtration rate (eGFR).
  • The model was developed using data from approximately 230,000 individuals with type 2 diabetes and externally validated in more than 217,000 participants.
  • SCORE2-Diabetes improves classification of individuals into moderate-, high-, and very-high-risk cardiovascular categories.

Validation and Clinical Relevance:

  • Multinational validation across 6.4 million individuals demonstrated overall C-statistics of approximately 0.70 for PREVENT and 0.68 for SCORE2.
  • Both models provide more comprehensive and contemporary cardiovascular risk assessment than traditional PCE-based approaches.

PREVENT and SCORE2-Diabetes represent important advances in cardiovascular risk prediction for people with diabetes. By incorporating diabetes-specific factors and broader cardiometabolic risk profiles, these models enable more precise risk stratification and support personalized cardiovascular prevention strategies

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top